|
TW321649B
(pt)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
WO1996033977A1
(en)
*
|
1995-04-27 |
1996-10-31 |
Zeneca Limited |
Quinazoline derivatives
|
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
BR9707495A
(pt)
|
1996-02-13 |
1999-07-27 |
Zeneca Ltd |
Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
|
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
|
AU719327B2
(en)
|
1996-03-05 |
2000-05-04 |
Astrazeneca Ab |
4-anilinoquinazoline derivatives
|
|
NZ332119A
(en)
|
1996-04-12 |
2001-08-31 |
Warner Lambert Co |
Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
|
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
TW436485B
(en)
*
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
|
WO1999024037A1
(en)
*
|
1997-11-06 |
1999-05-20 |
American Cyanamid Company |
Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
|
|
US6323209B1
(en)
*
|
1997-11-06 |
2001-11-27 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
|
HK1040720A1
(zh)
|
1998-05-15 |
2002-06-21 |
伊姆克罗尼系统公司 |
用辐射和生长因子受体酪氨酸激酶抑制剂治疗人肿瘤
|
|
TW533204B
(en)
*
|
1998-07-30 |
2003-05-21 |
Wyeth Corp |
A process for preparing substituted quinazoline derivatives
|
|
US6384223B1
(en)
|
1998-07-30 |
2002-05-07 |
American Home Products Corporation |
Substituted quinazoline derivatives
|
|
EE200100097A
(et)
*
|
1998-08-18 |
2002-06-17 |
The Regents Of The University Of California |
Hingamisteede lima tootmise tõkestamine EGF-R antagonistide manustamise teel
|
|
US7354894B2
(en)
*
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
EP1950201A1
(en)
*
|
1998-09-29 |
2008-07-30 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
|
AU2012209038B2
(en)
*
|
1998-09-29 |
2013-09-26 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
|
ID29800A
(id)
*
|
1999-02-27 |
2001-10-11 |
Boehringer Ingelheim Pharma |
Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase
|
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
|
US20040266834A1
(en)
*
|
1999-10-14 |
2004-12-30 |
Copland John A. |
Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
|
|
PL203782B1
(pl)
|
1999-11-05 |
2009-11-30 |
Astrazeneca Ab |
Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
|
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
|
DE60111515T2
(de)
*
|
2000-03-20 |
2006-05-11 |
OSI Pharmaceuticals, Inc., Uniondale |
Kombinationstherapie mit keratinozyten-wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
|
|
CA2403365A1
(en)
|
2000-04-07 |
2001-10-18 |
Astrazeneca Ab |
Quinazoline compounds
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
MXPA03001332A
(es)
|
2000-08-21 |
2004-07-08 |
Astrazeneca Ab |
Derivados de quinazolina.
|
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
EP1363627A2
(en)
|
2001-02-19 |
2003-11-26 |
Novartis AG |
Treatment of solid tumours with rapamycin derivatives
|
|
US6562319B2
(en)
*
|
2001-03-12 |
2003-05-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
|
|
CA2447139C
(en)
|
2001-05-11 |
2013-11-19 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
US20040167134A1
(en)
|
2001-05-16 |
2004-08-26 |
Christian Bruns |
Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
|
|
DE60234057D1
(de)
|
2001-07-25 |
2009-11-26 |
Raptor Pharmaceutical Inc |
Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
AU2003240655B2
(en)
|
2002-05-16 |
2007-09-06 |
Novartis Ag |
Use of EDG receptor binding agents in cancer
|
|
WO2004011456A1
(en)
*
|
2002-07-31 |
2004-02-05 |
Danter Wayne R |
Protein tyrosine kinase inhibitors
|
|
US7629347B2
(en)
*
|
2002-10-09 |
2009-12-08 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
EP2644195A1
(en)
|
2003-05-19 |
2013-10-02 |
Irm Llc |
Immunosuppressant Compounds and Compositions
|
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
|
JP4724657B2
(ja)
|
2003-05-30 |
2011-07-13 |
アストラゼネカ ユーケー リミテッド |
プロセス
|
|
DE602004004553T2
(de)
|
2003-09-19 |
2007-10-25 |
Astrazeneca Ab |
Chinazolinderivate
|
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
TW200529846A
(en)
|
2004-02-20 |
2005-09-16 |
Wyeth Corp |
3-quinolinecarbonitrile protein kinase inhibitors
|
|
BRPI0509721A
(pt)
|
2004-04-07 |
2007-09-25 |
Novartis Ag |
inibidores de iap
|
|
SI1746999T1
(sl)
|
2004-05-06 |
2012-01-31 |
Warner Lambert Co |
4-fenilamino-kinazolin-6-il-amidi
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
DE602005026865D1
(de)
|
2004-12-14 |
2011-04-21 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
|
BRPI0606839B8
(pt)
|
2005-02-03 |
2021-12-14 |
Massachusetts Gen Hospital |
Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr)
|
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
|
JP5054544B2
(ja)
|
2005-02-26 |
2012-10-24 |
アストラゼネカ アクチボラグ |
チロシンキナーゼ阻害剤としてのキナゾリン誘導体
|
|
LT1871347T
(lt)
|
2005-04-19 |
2016-11-10 |
Novartis Ag |
Farmacinė kompozicija
|
|
EP3827747A1
(en)
|
2005-04-28 |
2021-06-02 |
Otsuka Pharmaceutical Co., Ltd. |
Pharma-informatics system
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
DE602006018331D1
(de)
|
2005-09-20 |
2010-12-30 |
Astrazeneca Ab |
4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
|
|
RU2451524C2
(ru)
|
2005-11-04 |
2012-05-27 |
Вайет |
Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
|
|
ES2481671T3
(es)
|
2005-11-21 |
2014-07-31 |
Novartis Ag |
Inhibidores de mTOR en el tratamiento de tumores endocrinos
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
AU2007234382B2
(en)
|
2006-04-05 |
2011-06-09 |
Novartis Ag |
Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
|
|
MX2008012715A
(es)
|
2006-04-05 |
2008-10-14 |
Novartis Ag |
Combinaciones de agentes terapeuticos para el tratamiento de cancer.
|
|
MX2008014292A
(es)
|
2006-05-09 |
2008-11-18 |
Novartis Ag |
Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
|
|
CN101100466B
(zh)
*
|
2006-07-05 |
2013-12-25 |
天津和美生物技术有限公司 |
不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
|
|
ATE522625T1
(de)
|
2006-09-12 |
2011-09-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
|
|
KR20090071598A
(ko)
|
2006-09-18 |
2009-07-01 |
랩터 파마슈티컬 인코포레이티드 |
수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
|
|
EP2081933B1
(en)
|
2006-09-29 |
2011-03-23 |
Novartis AG |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
|
EP1921070A1
(de)
*
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
CA2673683C
(en)
|
2007-01-11 |
2014-07-29 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
|
WO2008091701A2
(en)
|
2007-01-25 |
2008-07-31 |
Dana-Farber Cancer Institute |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
|
US7998949B2
(en)
*
|
2007-02-06 |
2011-08-16 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
|
CA2677651A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
MX2009009782A
(es)
|
2007-03-15 |
2010-09-10 |
Ludwig Inst Cancer Res |
Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
|
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
WO2009067543A2
(en)
*
|
2007-11-19 |
2009-05-28 |
The Regents Of The University Of Colorado |
Treatment of histone deacetylase mediated disorders
|
|
EP2225226B1
(en)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Compounds and their use in a method for treatment of cancer
|
|
US9089572B2
(en)
*
|
2008-01-17 |
2015-07-28 |
California Institute Of Technology |
Inhibitors of p97
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
BRPI0907916A2
(pt)
*
|
2008-02-07 |
2015-07-28 |
Boehringer Ingelheim Int |
Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
|
|
KR101673621B1
(ko)
|
2008-03-24 |
2016-11-07 |
노파르티스 아게 |
아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제
|
|
ES2519474T3
(es)
|
2008-03-26 |
2014-11-07 |
Novartis Ag |
Inhibidores de las desacetilasas B basados en hidroxamato
|
|
SG191676A1
(en)
|
2008-06-17 |
2013-07-31 |
Wyeth Llc |
Antineoplastic combinations containing hki-272 and vinorelbine
|
|
WO2010006438A1
(en)
|
2008-07-17 |
2010-01-21 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
CN109464445A
(zh)
|
2008-08-04 |
2019-03-15 |
惠氏有限责任公司 |
4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
|
|
US8648191B2
(en)
*
|
2008-08-08 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
NZ603495A
(en)
*
|
2008-09-05 |
2014-05-30 |
Celgene Avilomics Res Inc |
Algorithm for designing irreversible inhibitors
|
|
ES2704986T3
(es)
|
2008-10-16 |
2019-03-21 |
Celator Pharmaceuticals Inc |
Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
|
|
AU2009327405A1
(en)
|
2008-12-18 |
2011-06-30 |
Novartis Ag |
New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
|
|
CN102256941A
(zh)
|
2008-12-18 |
2011-11-23 |
诺瓦提斯公司 |
新的盐
|
|
HRP20131106T1
(hr)
|
2008-12-18 |
2013-12-20 |
Novartis Ag |
Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
|
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
US20110281917A1
(en)
|
2009-01-29 |
2011-11-17 |
Darrin Stuart |
Substituted Benzimidazoles for the Treatment of Astrocytomas
|
|
ES2728225T3
(es)
|
2009-02-20 |
2019-10-23 |
2 Bbb Medicines B V |
Sistema de administración de fármacos a base de glutatión
|
|
EP2408817B1
(en)
|
2009-03-20 |
2016-03-16 |
F.Hoffmann-La Roche Ag |
Bispecific anti-her antibodies
|
|
SG174382A1
(en)
|
2009-04-06 |
2011-11-28 |
Wyeth Llc |
Treatment regimen utilizing neratinib for breast cancer
|
|
KR20190116576A
(ko)
|
2009-05-06 |
2019-10-14 |
라보라토리 스킨 케어, 인크. |
활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
|
|
KR101360725B1
(ko)
|
2009-06-26 |
2014-02-07 |
노파르티스 아게 |
Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
EA201200318A1
(ru)
|
2009-08-20 |
2012-09-28 |
Новартис Аг |
Гетероциклические оксимы
|
|
JP2013503129A
(ja)
|
2009-08-26 |
2013-01-31 |
ノバルティス アーゲー |
テトラ−置換ヘテロアリール化合物ならびにｍｄｍ２および／またはｍｄｍ４モジュレーターとしてのそれらの使用
|
|
AU2010294209A1
(en)
|
2009-09-10 |
2012-03-29 |
Irm Llc |
Ether derivatives of bicyclic heteroaryls
|
|
MX339811B
(es)
|
2009-09-16 |
2016-06-08 |
Celgene Avilomics Res Inc * |
Conjugados e inhibidores de cinasa de proteina.
|
|
EP2496575B1
(en)
|
2009-11-04 |
2014-04-30 |
Novartis AG |
Heterocyclic sulfonamide derivatives useful as mek inhibitors
|
|
JP2013510871A
(ja)
|
2009-11-12 |
2013-03-28 |
ジェネンテック， インコーポレイテッド |
樹状突起棘の密度を促す方法
|
|
EA201200617A1
(ru)
|
2009-11-23 |
2012-11-30 |
Серулин Фарма Инк. |
Полимеры на основе циклодекстрина для доставки лекарственных средств
|
|
CN102712648A
(zh)
|
2009-11-25 |
2012-10-03 |
诺瓦提斯公司 |
双环杂芳基的与苯稠合的6元含氧杂环衍生物
|
|
ES2484171T3
(es)
|
2009-12-08 |
2014-08-11 |
Novartis Ag |
Derivados de sulfonamidas heterocíclicas
|
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
US20110269244A1
(en)
|
2009-12-30 |
2011-11-03 |
Petter Russell C |
Ligand-directed covalent modification of protein
|
|
WO2011086053A1
(en)
|
2010-01-12 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
|
CN102146059A
(zh)
*
|
2010-02-08 |
2011-08-10 |
上海艾力斯医药科技有限公司 |
喹唑啉衍生物、制备方法及其应用
|
|
SG183333A1
(en)
|
2010-02-18 |
2012-09-27 |
Genentech Inc |
Neuregulin antagonists and use thereof in treating cancer
|
|
RU2012141536A
(ru)
|
2010-03-17 |
2014-04-27 |
Ф. Хоффманн-Ля Рош Аг |
Имидазопиридины, композиции и способы применения
|
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
|
CA2794952C
(en)
|
2010-04-01 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
|
CN103038643A
(zh)
|
2010-04-16 |
2013-04-10 |
基因泰克公司 |
作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a
|
|
MX342405B
(es)
|
2010-06-03 |
2016-09-28 |
Pharmacyclics Inc |
El uso de inhibidores de la tirosina quinasa de bruton (btk).
|
|
JP2013532149A
(ja)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
|
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
KR20130103734A
(ko)
|
2010-08-31 |
2013-09-24 |
제넨테크, 인크. |
바이오마커 및 치료 방법
|
|
BR112013006016A2
(pt)
|
2010-09-15 |
2016-06-07 |
Hoffmann La Roche |
compostos de azabenzotiazol, composições e métodos de uso
|
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
|
BR112013011520A2
(pt)
|
2010-11-19 |
2019-09-24 |
Hoffmann La Roche |
pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
|
|
MX2013007336A
(es)
|
2010-12-21 |
2013-08-01 |
Novartis Ag |
Compuestos de bi-heteroarilo como inhibidores de vps34.
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
CN103492390A
(zh)
|
2011-03-08 |
2014-01-01 |
诺瓦提斯公司 |
氟苯基双环杂芳基化合物
|
|
WO2012149413A1
(en)
|
2011-04-28 |
2012-11-01 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
|
KR20140034898A
(ko)
|
2011-06-09 |
2014-03-20 |
노파르티스 아게 |
헤테로시클릭 술폰아미드 유도체
|
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
|
EP2721007B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl isoquinolinone compounds
|
|
SG195067A1
(en)
|
2011-06-27 |
2013-12-30 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
CA2843499A1
(en)
|
2011-08-12 |
2013-02-21 |
F. Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
|
US12194002B2
(en)
|
2011-08-17 |
2025-01-14 |
Dennis Brown |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
|
|
CA2842375A1
(en)
|
2011-08-17 |
2013-02-21 |
Erica Jackson |
Neuregulin antibodies and uses thereof
|
|
EA026655B1
(ru)
|
2011-09-15 |
2017-05-31 |
Новартис Аг |
6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
|
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
|
EP2785717B1
(en)
|
2011-11-29 |
2016-01-13 |
Novartis AG |
Pyrazolopyrrolidine compounds
|
|
CA2857114A1
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
|
LT2794600T
(lt)
|
2011-12-22 |
2018-02-26 |
Novartis Ag |
2,3-dihidro-benzo[1,4]oksazino dariniai ir giminingi junginiai kaip fosfoinozitido-3 kinazės (pi3k) inhibitoriai, skirti gydymui, pavyzdžiui, reumatoidinio artrito
|
|
KR20140104047A
(ko)
|
2011-12-23 |
2014-08-27 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
|
EA201491259A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
|
|
EA201491268A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
|
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
|
EA201491265A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
|
|
US20140357633A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
|
CN104220457A
(zh)
|
2012-03-27 |
2014-12-17 |
霍夫曼-拉罗奇有限公司 |
涉及her3抑制剂的诊断和治疗
|
|
US20150297604A1
(en)
|
2012-04-03 |
2015-10-22 |
Novartis Ag |
Combination Products with Tyrosine Kinase Inhibitors and their Use
|
|
WO2013175417A1
(en)
|
2012-05-24 |
2013-11-28 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
|
US9789193B2
(en)
|
2012-06-15 |
2017-10-17 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
|
US9738643B2
(en)
|
2012-08-06 |
2017-08-22 |
Duke University |
Substituted indazoles for targeting Hsp90
|
|
EP3919069A1
(en)
|
2012-11-05 |
2021-12-08 |
Dana-Farber Cancer Institute, Inc. |
Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
MX374929B
(es)
|
2013-02-20 |
2025-03-06 |
Novartis Ag |
RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
|
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
|
KR20150123250A
(ko)
|
2013-03-06 |
2015-11-03 |
제넨테크, 인크. |
암 약물 내성의 치료 및 예방 방법
|
|
BR112015022545A2
(pt)
|
2013-03-13 |
2017-07-18 |
Constellation Pharmaceuticals Inc |
compostos de pirazolo e os usos disso
|
|
WO2014153030A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
WO2014152358A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
CN105339001A
(zh)
|
2013-03-15 |
2016-02-17 |
基因泰克公司 |
治疗癌症和预防癌症耐药性的方法
|
|
CN105246482A
(zh)
|
2013-03-15 |
2016-01-13 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
|
CN103304492B
(zh)
*
|
2013-06-20 |
2015-12-23 |
湖南欧亚生物有限公司 |
一种EGFR抑制剂Dacomitinib的合成方法
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
MX2016002794A
(es)
|
2013-09-05 |
2016-09-13 |
Genentech Inc |
Compuestos antiproliferativos.
|
|
AU2014321419B2
(en)
|
2013-09-22 |
2017-06-15 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
TW201605857A
(zh)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Ｃｄｋ８之醫療性抑制劑及其用途
|
|
TW201940514A
(zh)
|
2013-10-18 |
2019-10-16 |
美商建南德克公司 |
抗-rspo抗體及使用方法
|
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
|
|
CA2933883A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
|
EP3527587A1
(en)
|
2013-12-17 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
|
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
|
US10000469B2
(en)
|
2014-03-25 |
2018-06-19 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
|
EP3122729A4
(en)
|
2014-03-28 |
2017-11-15 |
Calitor Sciences, LLC |
Substituted heteroaryl compounds and methods of use
|
|
CN106103486B
(zh)
|
2014-03-31 |
2020-04-21 |
豪夫迈·罗氏有限公司 |
抗ox40抗体和使用方法
|
|
AU2015241038A1
(en)
|
2014-03-31 |
2016-10-13 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
|
|
RU2016140160A
(ru)
|
2014-04-03 |
2018-05-07 |
Инвиктус Онколоджи Пвт. Лтд. |
Супрамолекулярные комбинаторные лекарственные средства
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
JP6526789B2
(ja)
|
2014-07-31 |
2019-06-05 |
ノバルティス アーゲー |
組み合わせ療法
|
|
EP3181553B1
(en)
|
2014-08-15 |
2019-12-11 |
Arromax Pharmatech Co., Ltd. |
Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
|
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
|
JP2017529358A
(ja)
|
2014-09-19 |
2017-10-05 |
ジェネンテック， インコーポレイテッド |
がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用
|
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
|
MX2017005751A
(es)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
|
|
CN106796235B
(zh)
|
2014-11-03 |
2021-01-29 |
豪夫迈·罗氏有限公司 |
用于检测t细胞免疫子集的测定法及其使用方法
|
|
BR112017008628A2
(pt)
|
2014-11-06 |
2018-01-30 |
Genentech Inc |
terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit
|
|
EP3218376B1
(en)
|
2014-11-10 |
2019-12-25 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
CA2967368A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
CN107531690B
(zh)
|
2014-11-27 |
2020-11-06 |
基因泰克公司 |
用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
|
|
WO2016106340A2
(en)
|
2014-12-23 |
2016-06-30 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
|
JP6533997B2
(ja)
*
|
2014-12-26 |
2019-06-26 |
株式会社ヤクルト本社 |
Ｚｎｆ１４３阻害活性を有する化合物およびその利用
|
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
|
WO2016112284A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
|
WO2016112251A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
|
JP6659703B2
(ja)
|
2015-01-09 |
2020-03-04 |
ジェネンテック， インコーポレイテッド |
ピリダジノン誘導体および癌の処置におけるそれらの使用
|
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
MX2017012805A
(es)
|
2015-04-07 |
2018-04-11 |
Genentech Inc |
Complejo de unión a antígenos con actividad agonista y métodos de uso.
|
|
AU2016262074A1
(en)
|
2015-05-12 |
2017-11-09 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
MX392671B
(es)
|
2015-05-29 |
2025-03-24 |
Genentech Inc |
Antagonistas de unión a pd-l1 y usos de los mismos para el tratamiento de cáncer
|
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
|
KR20180025888A
(ko)
|
2015-06-08 |
2018-03-09 |
제넨테크, 인크. |
항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
|
|
KR102689256B1
(ko)
|
2015-06-17 |
2024-07-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
|
ES2862727T3
(es)
|
2015-08-26 |
2021-10-07 |
Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio |
Compuestos tricíclicos condensados como inhibidores de proteínas quinasas
|
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
|
NZ739750A
(en)
|
2015-09-25 |
2019-11-29 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
AU2016369528B2
(en)
|
2015-12-16 |
2021-04-22 |
Genentech, Inc. |
Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
|
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
|
US10710968B2
(en)
|
2016-01-13 |
2020-07-14 |
Hadasit Medical Research Services And Development Ltd. |
Radiolabeled erlotinib analogs and uses thereof
|
|
EP4155415A1
(en)
|
2016-02-29 |
2023-03-29 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
KR20180134347A
(ko)
|
2016-04-15 |
2018-12-18 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
|
PL3443350T3
(pl)
|
2016-04-15 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Sposoby monitorowania i leczenia nowotworu
|
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
|
WO2017205536A2
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
MA45146A
(fr)
|
2016-05-24 |
2021-03-24 |
Constellation Pharmaceuticals Inc |
Dérivés de pyrazolopyridine pour le traitement du cancer
|
|
US20200129519A1
(en)
|
2016-06-08 |
2020-04-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック， インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
|
WO2018039205A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
|
WO2018064076A1
(en)
|
2016-09-27 |
2018-04-05 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
|
CN110418851A
(zh)
|
2016-10-06 |
2019-11-05 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
|
AU2018228873A1
(en)
|
2017-03-01 |
2019-08-29 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
|
IL271888B2
(en)
|
2017-07-21 |
2024-09-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
AU2018316343B2
(en)
|
2017-08-11 |
2025-06-12 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
|
JP7530829B2
(ja)
|
2017-09-08 |
2024-08-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの診断及び治療方法
|
|
KR20200100598A
(ko)
|
2017-09-26 |
2020-08-26 |
세로 테라퓨틱스, 인코포레이티드 |
키메라 포식작용 수용체 분자 및 사용 방법
|
|
AU2018353984A1
(en)
|
2017-10-24 |
2020-05-07 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
|
WO2019084395A1
(en)
|
2017-10-27 |
2019-05-02 |
University Of Virginia Patent Foundation |
COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
|
|
KR20200075860A
(ko)
|
2017-11-06 |
2020-06-26 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
JP7021356B2
(ja)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ |
ピリミジン誘導体系キナーゼ阻害剤類
|
|
SG11202006441SA
(en)
|
2018-01-15 |
2020-08-28 |
Epiaxis Therapeutics Pty Ltd |
Agents and methods for predicting response to therapy
|
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
JP7391027B2
(ja)
|
2018-02-26 |
2023-12-04 |
ジェネンテック， インコーポレイテッド |
抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体による治療のための投薬
|
|
US12291557B2
(en)
|
2018-03-28 |
2025-05-06 |
Cero Therapeutics Holdings, Inc. |
Chimeric TIM4 receptors and uses thereof
|
|
MX2020010235A
(es)
|
2018-03-28 |
2020-10-28 |
Cero Therapeutics Inc |
Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
|
|
WO2019191340A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
|
AU2019275404A1
(en)
|
2018-05-21 |
2020-12-03 |
Bruker Spatial Biology, Inc. |
Molecular gene signatures and methods of using same
|
|
JP7399895B2
(ja)
|
2018-06-23 |
2023-12-18 |
ジェネンテック， インコーポレイテッド |
Ｐｄ－１軸結合拮抗薬、白金剤、およびトポイソメラーゼｉｉ阻害剤で肺癌を治療する方法
|
|
BR112021000673A2
(pt)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
|
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
|
CN112805267B
(zh)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
用作tead调节剂的甲酰胺和磺酰胺衍生物
|
|
CN112955747A
(zh)
|
2018-09-19 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
膀胱癌的治疗和诊断方法
|
|
JP7475336B2
(ja)
|
2018-09-21 |
2024-04-26 |
ジェネンテック， インコーポレイテッド |
トリプルネガティブ乳癌のための診断方法
|
|
AU2019362972A1
(en)
|
2018-10-17 |
2021-05-20 |
The University Of Queensland |
Epigenetic biomarker and uses therefor
|
|
AU2019361983A1
(en)
|
2018-10-18 |
2021-05-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
WO2020131627A1
(en)
|
2018-12-19 |
2020-06-25 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
JP2022515197A
(ja)
|
2018-12-19 |
2022-02-17 |
アレイ バイオファーマ インコーポレイテッド |
がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
|
|
CN113396230A
(zh)
|
2019-02-08 |
2021-09-14 |
豪夫迈·罗氏有限公司 |
癌症的诊断和治疗方法
|
|
BR112021016923A2
(pt)
|
2019-02-27 |
2021-11-03 |
Genentech Inc |
Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
|
|
JP7520389B2
(ja)
|
2019-02-27 |
2024-07-23 |
エピアクシス セラピューティクス プロプライエタリー リミテッド |
Ｔ細胞機能を評価して治療法に対する応答を予測するための方法および薬剤
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
MX2021013222A
(es)
|
2019-05-03 |
2022-01-06 |
Genentech Inc |
Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
TWI873176B
(zh)
|
2019-09-04 |
2025-02-21 |
美商建南德克公司 |
Ｃｄ８結合劑及其用途
|
|
WO2021062085A1
(en)
|
2019-09-27 |
2021-04-01 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
US20240058446A1
(en)
|
2019-10-03 |
2024-02-22 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
EP4051674A1
(en)
|
2019-10-29 |
2022-09-07 |
F. Hoffmann-La Roche AG |
Bifunctional compounds for the treatment of cancer
|
|
JP2022553803A
(ja)
|
2019-11-06 |
2022-12-26 |
ジェネンテック， インコーポレイテッド |
血液がんの処置のための診断方法及び治療方法
|
|
KR20220101138A
(ko)
|
2019-11-13 |
2022-07-19 |
제넨테크, 인크. |
치료적 화합물 및 사용 방법
|
|
EP4058465A1
(en)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4 antagonist peptides
|
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
IL294800A
(en)
|
2020-01-27 |
2022-09-01 |
Genentech Inc |
Methods for treatment of cancer with an anti-tigit antagonist antibody
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
|
JP2023520515A
(ja)
|
2020-04-03 |
2023-05-17 |
ジェネンテック， インコーポレイテッド |
がんに対する治療方法及び診断方法
|
|
EP4136228A4
(en)
|
2020-04-15 |
2024-09-11 |
California Institute of Technology |
THERMAL REGULATION OF T-CELL IMMUNOTHERAPY BY MOLECULAR AND PHYSICAL ACTUATION
|
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
|
MX2022015881A
(es)
|
2020-06-18 |
2023-01-24 |
Genentech Inc |
Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
|
EP4192509A1
(en)
|
2020-08-05 |
2023-06-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
|
WO2022047259A1
(en)
|
2020-08-28 |
2022-03-03 |
California Institute Of Technology |
Synthetic mammalian signaling circuits for robust cell population control
|
|
MX2023003338A
(es)
|
2020-09-23 |
2023-06-14 |
Erasca Inc |
Piridonas y pirimidonas tricíclicas.
|
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
KR20230146052A
(ko)
|
2021-02-12 |
2023-10-18 |
에프. 호프만-라 로슈 아게 |
암 치료용 비시클릭 테트라히드로아제핀 유도체
|
|
MX2023009910A
(es)
|
2021-02-26 |
2023-11-09 |
Kelonia Therapeutics Inc |
Vectores lentivirales dirigidos a los linfocitos.
|
|
EP4347603A1
(en)
|
2021-05-25 |
2024-04-10 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
KR20240119868A
(ko)
|
2021-07-28 |
2024-08-06 |
세로 테라퓨틱스, 인코포레이티드 |
키메라 tim4 수용체 및 이의 용도
|
|
TW202321261A
(zh)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性ｋｒａｓ抑制劑
|
|
WO2023051687A1
(zh)
*
|
2021-09-30 |
2023-04-06 |
北京赛特明强医药科技有限公司 |
一种喹唑啉类化合物、组合物及其应用
|
|
JP2024543912A
(ja)
|
2021-11-24 |
2024-11-26 |
ジェネンテック， インコーポレイテッド |
二環式治療用化合物及びがんの処置における使用方法
|
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
|
CA3246312A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
|
|
AU2022458320A1
(en)
|
2022-05-11 |
2024-11-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CA3257760A1
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
PROGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
|
|
EP4554978A1
(en)
|
2022-07-13 |
2025-05-21 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CN119604530A
(zh)
|
2022-07-19 |
2025-03-11 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
PE20250876A1
(es)
|
2022-08-11 |
2025-03-28 |
Hoffmann La Roche |
Derivados biciclicos de tetrahidrotiazepina
|
|
KR20250038674A
(ko)
|
2022-08-11 |
2025-03-19 |
에프. 호프만-라 로슈 아게 |
바이시클릭 테트라히드로티아제핀 유도체
|
|
JP2025526726A
(ja)
|
2022-08-11 |
2025-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二環式テトラヒドロアゼピン誘導体
|
|
JP2025538859A
(ja)
|
2022-10-21 |
2025-12-02 |
公益財団法人川崎市産業振興財団 |
非吸着性またはスーパーステルス小胞
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
TW202434206A
(zh)
|
2023-02-17 |
2024-09-01 |
美商伊瑞斯卡公司 |
Ｋｒａｓ抑制劑
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TW202504641A
(zh)
|
2023-06-08 |
2025-02-01 |
美商建南德克公司 |
用於淋巴瘤之診斷及治療方法的巨噬細胞特徵
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|